91 related articles for article (PubMed ID: 228493)
1. [Chemistry and biology of hypothalamic cardioactive proteins and peptides].
Galoian AA
Vopr Biokhim Mozga; 1978; 13():9-38. PubMed ID: 228493
[TBL] [Abstract][Full Text] [Related]
2. [Inhibition of rat heart and brain cyclic adenosine-3',5'-monophosphate phosphodiesterase in vitro under the influence of neurohormone C].
Galoian AA; Gurvits BIa; Pogosian MA
Biull Eksp Biol Med; 1977 Jun; 83(6):691-3. PubMed ID: 195650
[TBL] [Abstract][Full Text] [Related]
3. Protein-hormonal complexes of the hypothalamus as neurochemical systems of regulation.
Galoyan A; Srapionian R
Neurochem Res; 1983 Dec; 8(12):1511-35. PubMed ID: 6143276
[No Abstract] [Full Text] [Related]
4. Selective phosphodiesterase inhibition and alterations of cardiac function by alkylated xanthines.
Mushlin P; Boerth RC; Wells JN
Mol Pharmacol; 1981 Jul; 20(1):179-89. PubMed ID: 6270531
[No Abstract] [Full Text] [Related]
5. Pharmacological inhibition of calmodulin-sensitive phosphodiesterases.
Ilien B; Ruckstuhl M; Landry Y
J Pharmacol; 1982; 13(2):307-16. PubMed ID: 6285085
[TBL] [Abstract][Full Text] [Related]
6. [Inhibition of rat heart and brain cyclic 3',5'-adenosine monophosphate phosphodiesterase under the influence of neurohormone "C"].
Galoian AA; Gurvits BIa; Pogosian MA
Vopr Biokhim Mozga; 1976; 11():89-96. PubMed ID: 203105
[TBL] [Abstract][Full Text] [Related]
7. [Breakdown of luliberin, somatostatin and substance P as an effect of hypothalamic endopeptidases].
Akopian TN; Arutiunian AA; Laĭta A; Galoian AA
Vopr Biokhim Mozga; 1978; 13():189-205. PubMed ID: 41363
[TBL] [Abstract][Full Text] [Related]
8. Regulation of multiple forms of cyclic nucleotide phosphodiesterase from bovine hypothalamus: new factors modulating enzyme activity.
Galoyan AA; Gurvitz BYa
Neurochem Res; 1985 Nov; 10(11):1467-81. PubMed ID: 3003614
[TBL] [Abstract][Full Text] [Related]
9. [Molecular mechanisms of hypothalamic hexapeptide regulation of the links in glycogen metabolism].
Galoian AA; Abelian ZhG; Baev VV; Ter-Tatevosian LP; Parsadanian GK
Vopr Med Khim; 1979; 25(3):285-8. PubMed ID: 222071
[TBL] [Abstract][Full Text] [Related]
10. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
11. Endogenous peptides that inhibit brain cyclic AMP phosphodiesterase.
Collier HO; Butt NM; Saeed SA
J Neurochem; 1982 Jan; 38(1):275-7. PubMed ID: 6286880
[TBL] [Abstract][Full Text] [Related]
12. [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].
Medvedeva MV
Biokhimiia; 1995 Mar; 60(3):364-86. PubMed ID: 7734612
[TBL] [Abstract][Full Text] [Related]
13. [Separation and investigation of the regulatory properties of two forms of cyclic nucleotide phosphodiesterase from rabbit heart--sensitive and insensitive to Ca-dependent regulator protein].
Tkachuk VA; Lazarevich VG; Men'shikov MIu; Severin SE
Biokhimiia; 1978 Sep; 43(9):1622-30. PubMed ID: 214170
[TBL] [Abstract][Full Text] [Related]
14. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics.
Weishaar RE; Quade MM; Schenden JA; Evans DB
J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(6):551-64. PubMed ID: 3003170
[TBL] [Abstract][Full Text] [Related]
15. [Cardiotropic effects of luliberin. Effects of luliberin on the activities of phosphorylase A and ornithine decarboxylase and concentration of 3', 5'-AMP].
Isachenkov VA; Bakalkin GIa; Iatygin KN; Komissarova EN; Tsibezov VV
Biokhimiia; 1979 Feb; 44(2):233-9. PubMed ID: 219912
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
Murray F; MacLean MR; Pyne NJ
Br J Pharmacol; 2002 Dec; 137(8):1187-94. PubMed ID: 12466227
[TBL] [Abstract][Full Text] [Related]
17. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
[TBL] [Abstract][Full Text] [Related]
18. Studies on griseolic acid derivatives. I. Synthesis of substituted derivatives of griseolic acid at the N1, C6, C2' or C7' position and their biological activities.
Kaneko M; Murofushi Y; Kimura M; Yamazaki M; Iijima Y
Nucleic Acids Symp Ser; 1985; (16):89-92. PubMed ID: 3003711
[TBL] [Abstract][Full Text] [Related]
19. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
Kass DA
Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
[No Abstract] [Full Text] [Related]
20. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.
Hidaka H; Hayashi H; Kohri H; Kimura Y; Hosokawa T; Igawa T; Saitoh Y
J Pharmacol Exp Ther; 1979 Oct; 211(1):26-30. PubMed ID: 226672
[No Abstract] [Full Text] [Related]
[Next] [New Search]
